|
COPYRIGHT 2008 M2 Communications Ltd.
M2 PRESSWIRE-12 March 2008-The SI Report: Global Review for CombinatoRx, Incorporated(C)1994-2008 M2 COMMUNICATIONS LTD
RDATE:12032008
Streetinvesting.com has now resumed our progressive review of CombinatoRx, Incorporated (NASDAQ: CRXX) after it traded up 1% Wednesday, early in the morning with average volume. Based on the Company's most recent news release, we will be progressively reviewing the impact of the markets and the effects of their developments.
Make sure to visit www.streetinvesting.com to keep updated and signup for free with no credit card for market reports and analytical plays.
Our research resources have been aimed towards the US Large Caps and the various prospective companies therein CombinatoRx, Incorporated was among those that we have been closely examining due to their recent news and trading patterns.
March 12, 2008 CombinatoRx, Incorporated (NASDAQ: CRXX) announced top line results of its randomized, blinded, placebo-controlled Phase 2 proof-of-concept clinical trial of CRx-191 in plaque psoriasis. CRx-191 is...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
